JAZZ PHARMACEUTICALS FRANCE
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT01606176
- Locations
- 🇬🇧
James Paget Hospital, Norfolk, United Kingdom
A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT01606189
- Locations
- 🇬🇧
The Royal National Orthopaedic Hospital, Middlesex, United Kingdom
A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT01604265
- Locations
- 🇬🇧
Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom
A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 337
- Registration Number
- NCT01599234
- Locations
- 🇬🇧
The Royal Berkshire and Battle Hospitals NHS Trust, Reading, United Kingdom
Phase I Study of mPEG-R-Crisantaspase Given IV
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT01551524
- Locations
- 🇫🇷
Centre Henri Becquerel, Rouen, Cedex, France
🇫🇷Institut Claudius Regaud, Toulouse, France
🇫🇷Hôpital Henri Mondor, Créteil, France
A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT01485770
- Locations
- 🇺🇸
SleepMed of South Carolina, Columbia, South Carolina, United States
🇺🇸The Center for Sleep and Wake Disorders, Chevy Chase, Maryland, United States
🇺🇸Future Search Trials of Neurology, Austin, Texas, United States
A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 406
- Registration Number
- NCT01424566
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
- First Posted Date
- 2011-05-27
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 399
- Registration Number
- NCT01361607
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 660
- Registration Number
- NCT01337089
Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT01323465
- Locations
- 🇬🇧
Guy's Drug Research Unit, Quintiles Ltd., London, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath